Saltar al contenido principal

ETHNOS_APP

Inicio • Búsqueda • Revistas • Lista 0

PrEPped for Covid? The association between HIV-PrEP use and Covid-19 among men and gender diverse people who have sex with men

Findings from three large online surveys in the United Kingdom

Datos Bibliográficos

ID15375452
AutoresCaisey V Pulford (0000-0003-2500-9119, The George Institute for Global Health, autor de correspondencia), Holly Mitchell (0000-0002-6103-9975, Public Health England), Jack RG Brown (0000-0003-1334-8658, National Institute for Health and Care Research), Alison Howarth (0000-0002-0597-6614, National Institute for Health and Care Research), Alison R Howarth, David Reid (0000-0002-8743-2070, National Institute for Health and Care Research), Hamish Mohammed (0000-0002-2060-7286, Public Health England), Gwenda Hughes (0000-0003-2090-7702, Public Health England), Catherine H Mercer (0000-0002-4220-5034, National Institute for Health and Care Research), John Saunders (0000-0003-3020-9916, Public Health England)
Año2026
Volumen26
Número1
Páginas624-624
Fecha de publicación2026-01-22
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaBMC Public Health (JOURNAL)
Identificadores de la revistaISSN: 1471-2458 • E-ISSN: 1471-2458
EditorialBioMed Central (PUBLISHER • GB)
DOI10.1186/s12889-025-26127-0
PMID41572245
OpenAlexW7125364365
IdiomaEN
Referencias citadas29

Oral tenofovir and emtricitabine taken as pre-exposure prophylaxis (HIV-PrEP) is highly effective at reducing Human Immunodeficiency Virus (HIV) acquisition. Nucleotide analogues have also been shown to inhibit Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) polymerase activity in vitro, raising the question as to whether tenofovir-based HIV-PrEP could be useful for the prevention and treatment of COVID-19. We sought to examine the association between HIV-PrEP use and self-reported COVID-19 testing outcomes and respiratory symptoms among men and gender diverse people who have sex with men in the UK. Participants completed online surveys deployed at three time points during the COVID-19 pandemic (Survey 1 (S1) 23/06/20 − 14/07/20; S2 23/11/20 − 12/12/20; S3 23/03/21 − 14/04/21), including men (cis/transgender), transwomen or gender-diverse people reporting sex with another man (cis/transgender) or non-binary person assigned male at birth. The outcome was self-reported COVID-19 testing and COVID-19 related respiratory symptoms including a new continuous cough, high temperature or loss of smell and/or taste during the most recent lookback period. All participants reporting taking HIV-PrEP in the past year were compared with those who did not. Analysis was performed using logistic regression, adjusting for sociodemographic and behavioural factors. Among 4,544 participants living without HIV across three surveys (89.7% of all survey respondents), 21.4% (n = 970) reported recently using HIV-PrEP, 564 (12.4%) participants reported respiratory symptoms and 160 (3.5%) reported a positive COVID-19 test. There was a slight, non-statistically significant positive association between HIV-PrEP use and a COVID-19 positive test in the first survey-period (P1) (adjusted Odds Ratio (aOR) = 1.11, CI = 0.51–3.98). This positive association significantly increased across survey periods (P2: aOR = 4.26, CI = 1.21–14.97, P3: aOR = 9.02, CI = 2.69–30.31). There was a positive association between HIV-PrEP use and respiratory symptoms in the first survey-period (aOR = 1.45, CI = 1.03–2.03). However, this positive association reversed in survey-period 2 and 3 (P2: aOR = 0.62, CI = 0.40–0.95, P3: aOR = 0.45, CI = 0.28–0.72). We found no evidence that HIV-PrEP use protected against COVID-19 among participants. Conversely, we identified a positive association between HIV-PrEP use and COVID-19 which may reflect uncaptured behaviours that increase COVID-19 exposure amongst those using HIV-PrEP. The decline in respiratory symptoms in HIV-PrEP users over time might reflect some immune protection following exposures to respiratory viruses through more social mixing or a direct impact of HIV-PrEP on symptom severity

Biostatistics · Emtricitabine · Logistic regression · Men who have sex with men · Odds · Odds ratio · Pandemic · Public health · HIV Research and Treatment · HIV-related health complications and treatments · HIV/AIDS Research and Interventions · Epidemiology

  • X. On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling

    Karl Pearson•The London, Edinburgh, and Dublin…•1900

  • The Impact of First UK-Wide Lockdown (March–June 2020) on Sexual Behaviors in Men and Gender Diverse People Who Have Sex with Men During the Covid-19 Pandemic

    Open Access•Tom Nadarzynski, Will Nutland et al.•Archives of Sexual Behavior•2023

  • Covid-19 infection and vaccination uptake in men and gender-diverse people who have sex with men in the UK

    Open Access•Dana Ogaz, Hester Allen et al.•BMC Public Health•2023

  • PrEP Use, Sexual Behaviour, and PrEP Adherence Among Men who have Sex with Men Living in Wales Prior to and During the Covid-19 Pandemic

    Open Access•David Gillespie, Zoë Couzens et al.•AIDS and Behavior•2022

  • Adjusting Behavioural Surveillance and Assessing Disparities in the Impact of Covid-19 on Gay and Bisexual Men’s HIV-Related Behaviour in Australia

    Open Access•Martin Holt, Curtis Chan et al.•AIDS and Behavior•2022

Velocidad de citaciónhistorical
Altamente citadoNo
Ethnos_APP • Proyecto Open Source • Licencia MIT • Frontend v2.0.0 • Privacidad y Cookies • Documentación de la API: api.ethnos.app/docs • Código de la API: GitHub • DOI: 10.5281/zenodo.17049435 • Código del Frontend: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae